Photo by sebastiaanstam from unsplash
Combined biomarker ratios have potential prognostic value in various cancers. The neutrophil-to-lymphocyte ratio, lymphocyte-to-monocyte ratio (LMR), platelet-tolymphocyte ratio, and fibrinogen-to-albumin ratio have been used as prognostic biomarkers for pancreatic ductal… Click to show full abstract
Combined biomarker ratios have potential prognostic value in various cancers. The neutrophil-to-lymphocyte ratio, lymphocyte-to-monocyte ratio (LMR), platelet-tolymphocyte ratio, and fibrinogen-to-albumin ratio have been used as prognostic biomarkers for pancreatic ductal adenocarcinoma (PDAC). Although the usefulness of various prognostic factors has been reported, the most effective pre-operative biomarker for PDAC patients has not yet been established. Preoperative evaluation using predictors of long-term prognosis can be useful in determining the appropriate treatment for PDAC.
Journal Title: Annals of Surgical Oncology
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!